Paysign Toekomstige groei

Future criteriumcontroles 1/6

De winst van Paysign zal naar verwachting dalen met 24.1% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 10.6% per jaar. De winst per aandeel zal naar verwachting afnemen met 23.8% per jaar.

Belangrijke informatie

-24.1%

Groei van de winst

-23.8%

Groei van de winst per aandeel

Diversified Financial winstgroei	-5.6%
Inkomstengroei	10.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	06 Nov 2024

Recente toekomstige groei-updates

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02

Recent updates

Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth

Nov 20

Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?

Sep 07

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02

Paysign: Expect Rapid Growth In Its Pharma Business

Jun 30

Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Apr 26

Earnings Update: Here's Why Analysts Just Lifted Their PaySign, Inc. (NASDAQ:PAYS) Price Target To US$3.75

Aug 13

Calculating The Fair Value Of PaySign, Inc. (NASDAQ:PAYS)

Jun 14

At US$1.42, Is PaySign, Inc. (NASDAQ:PAYS) Worth Looking At Closely?

May 16

PaySign: A 'Backdoor' $2 Stagflation Play

Mar 29

Paysign: My Top Rebound Pick For 2022

Dec 28

Paysign: The Plasma Toll Booth

Sep 23

PaySign's Post-Pandemic Payoff

Sep 07

Why PaySign Is A Very Good Company

Dec 28

PaySign: Long-Term Story Still Intact

Dec 21

Paysign reports Q3 results

Nov 17

Winst- en omzetgroeiprognoses

NasdaqCM:PAYS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	71	4	N/A	N/A	2
12/31/2025	66	5	N/A	N/A	4
12/31/2024	58	3	N/A	N/A	4
9/30/2024	56	8	23	32	N/A
6/30/2024	54	8	48	56	N/A
3/31/2024	50	7	25	33	N/A
12/31/2023	47	6	21	28	N/A
9/30/2023	44	2	-8	-1	N/A
6/30/2023	42	1	4	9	N/A
3/31/2023	40	1	18	23	N/A
12/31/2022	38	1	21	25	N/A
9/30/2022	36	0	27	30	N/A
6/30/2022	33	-1	11	14	N/A
3/31/2022	31	-1	8	10	N/A
12/31/2021	29	-3	13	15	N/A
9/30/2021	28	-7	14	17	N/A
6/30/2021	20	-13	25	27	N/A
3/31/2021	20	-12	10	13	N/A
12/31/2020	24	-9	10	14	N/A
9/30/2020	27	-3	14	18	N/A
6/30/2020	36	6	-2	3	N/A
3/31/2020	38	8	3	7	N/A
12/31/2019	35	7	13	17	N/A
9/30/2019	32	6	16	18	N/A
6/30/2019	29	4	27	29	N/A
3/31/2019	26	3	33	34	N/A
12/31/2018	23	3	14	16	N/A
9/30/2018	21	2	10	12	N/A
6/30/2018	19	2	N/A	10	N/A
3/31/2018	17	2	N/A	7	N/A
12/31/2017	15	2	N/A	7	N/A
9/30/2017	14	2	N/A	6	N/A
6/30/2017	12	2	N/A	3	N/A
3/31/2017	11	2	N/A	5	N/A
12/31/2016	10	1	N/A	4	N/A
9/30/2016	10	1	N/A	1	N/A
6/30/2016	9	-2	N/A	3	N/A
3/31/2016	9	-2	N/A	0	N/A
12/31/2015	8	-2	N/A	-1	N/A
9/30/2015	11	0	N/A	3	N/A
6/30/2015	11	3	N/A	3	N/A
3/31/2015	9	2	N/A	2	N/A
12/31/2014	10	3	N/A	3	N/A
9/30/2014	7	0	N/A	1	N/A
6/30/2014	7	0	N/A	0	N/A
3/31/2014	7	0	N/A	0	N/A
12/31/2013	6	1	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van PAYS zal naar verwachting de komende 3 jaar dalen ( -24.1% per jaar).

Winst versus markt: De winst van PAYS zal naar verwachting de komende 3 jaar dalen ( -24.1% per jaar).

Hoge groeiwinsten: De winst van PAYS zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van PAYS ( 10.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van PAYS ( 10.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PAYS naar verwachting over 3 jaar hoog zal zijn

Paysign Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates increase by 26%

Paysign, Inc. Reiterates Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 22%, revenue upgraded

Price target increased by 7.5% to US$6.58

Paysign, Inc. Revises Earnings Guidance for the Full Year 2024

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth

Investor sentiment deteriorates as stock falls 15%

Chief Payments Officer & Director recently sold US$100k worth of stock

Consensus EPS estimates increase by 26%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Paysign, Inc. Reiterates Earnings Guidance for the Year 2024

Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?

New minor risk - Insider selling

Consensus EPS estimates fall by 22%, revenue upgraded

Price target increased by 7.5% to US$6.58

Paysign, Inc. Revises Earnings Guidance for the Full Year 2024

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Paysign, Inc. Revises Earnings Guidance for the Full Year 2024

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improves as stock rises 34%

Paysign: Expect Rapid Growth In Its Pharma Business

Independent Director exercised options to buy US$85k worth of stock.

Consensus EPS estimates increase by 33%

Price target increased by 8.9% to US$6.13

First quarter 2024 earnings released: EPS: US$0.006 (vs US$0.003 loss in 1Q 2023)

Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

Consensus EPS estimates fall by 30%, revenue upgraded

PaySign, Inc., Annual General Meeting, May 03, 2024

Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching

Price target increased by 14% to US$5.25

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CFO & Treasurer exercised options and sold US$79k worth of stock

PaySign, Inc. Announces Executive Changes

Revenues Tell The Story For PaySign, Inc. (NASDAQ:PAYS)

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of the Common Stock of Paysign, Inc

Consensus EPS estimates increase by 25%

New major risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Market cap size

Consensus EPS estimates fall by 50%

PaySign, Inc. Reaffirms Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0.004 loss in 2Q 2022)

Co-Founder exercised options and sold US$71k worth of stock

New minor risk - Market cap size

Consensus EPS estimates fall by 20%

First quarter 2023 earnings released: US$0.003 loss per share (vs US$0.006 loss in 1Q 2022)

Consensus EPS estimates increase by 36%

Price target increased by 13% to US$4.31

CFO & Treasurer recently sold US$101k worth of stock

PaySign, Inc. Elects Jeffrey B. Newman to Its Board of Directors

Consensus EPS estimates have been upgraded.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

PaySign, Inc. Provides Earnings Guidance for the Fiscal Year 2022

General Counsel exercised options to buy US$54k worth of stock.

The Recovery At PaySign Has Legs

Earnings Update: Here's Why Analysts Just Lifted Their PaySign, Inc. (NASDAQ:PAYS) Price Target To US$3.75

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$3.75

PaySign, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2022

Calculating The Fair Value Of PaySign, Inc. (NASDAQ:PAYS)

At US$1.42, Is PaySign, Inc. (NASDAQ:PAYS) Worth Looking At Closely?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PaySign, Inc. Provides Earnings Guidance for the Full Year of 2022

PaySign, Inc. Provides Earnings Guidance for the Full Year of 2022

Price target decreased to US$3.44

Insufficient new directors

Price target decreased to US$3.44

Insufficient new directors

PaySign: A 'Backdoor' $2 Stagflation Play

Paysign: My Top Rebound Pick For 2022

Paysign: The Plasma Toll Booth

PaySign's Post-Pandemic Payoff